268 related articles for article (PubMed ID: 15749809)
1. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
Uçkaya G; Delagrange P; Chavanieu A; Grassy G; Berthault MF; Ktorza A; Cerasi E; Leibowitz G; Kaiser N
J Endocrinol; 2005 Mar; 184(3):505-13. PubMed ID: 15749809
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
4. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
5. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
6. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
7. Islet amyloid polypeptide in Psammomys obesus (sand rat): effects of nutritionally induced diabetes and recovery on low-energy diet or vanadyl sulfate treatment.
Leckström A; Ziv E; Shafrir E; Westermark P
Pancreas; 1997 Nov; 15(4):358-66. PubMed ID: 9361089
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
[TBL] [Abstract][Full Text] [Related]
9. The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ; Nauck MA
Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
11. Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus.
Hefetz S; Ziv E; Jörns A; Lenzen S; Shafrir E
Diabetes Metab Res Rev; 2006; 22(2):139-45. PubMed ID: 16088969
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA; Vahl TP
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
[TBL] [Abstract][Full Text] [Related]
13. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 C-terminal structures affect its blood glucose lowering-function.
Li Y; Shi C; Lv Q; Zhang H; Li B; Bian G; Huang Q; Zhang W; Xue X; Ren X; Gao H; Sun C; Wang J; Zhang M
J Pept Sci; 2008 Jul; 14(7):777-85. PubMed ID: 18200618
[TBL] [Abstract][Full Text] [Related]
15. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
16. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Göke B; Hoppe B; Konrad A; Schirra J
Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
[No Abstract] [Full Text] [Related]
17. [Type 2 diabetes and beta cell apoptosis].
Cerasi E; Kaiser N; Leibowitz G
Diabetes Metab; 2000 Jun; 26 Suppl 3():13-6. PubMed ID: 10945145
[TBL] [Abstract][Full Text] [Related]
18. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
Zander M; Madsbad S; Madsen JL; Holst JJ
Lancet; 2002 Mar; 359(9309):824-30. PubMed ID: 11897280
[TBL] [Abstract][Full Text] [Related]
19. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
20. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
